A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms

mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment

(2017) Melissa A. Orr-Asman et al.   MOLECULAR CANCER THERAPEUTICS

Doubling Down on mTOR Inhibition: Harnessing ZEBRA for Insights

(2016) Jason Yongsheng Chan et al.   EUROPEAN UROLOGY

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

(2016) James C Yao et al.   LANCET

Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer

(2016) Fernanda Musa et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease

(2016) Helma Freitag et al.   NEUROENDOCRINOLOGY

Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management

(2016) Jonathan W. Goldman et al.   ONCOLOGIST

Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature

(2016) Antongiulio Faggiano et al.   ONCOLOGIST

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

(2015) Johanna C. Bendell et al.   CANCER

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

(2015) D. S. Mortensen et al.   MOLECULAR CANCER THERAPEUTICS

Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth

(2015) Aarthi Kannan et al.   Oncotarget

Strategies for the management of adverse events associated with mTOR inhibitors

(2014) Bruce Kaplan et al.   Transplantation Reviews

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY